about
Vitamin B and its derivatives for diabetic kidney diseaseGlucose targets for preventing diabetic kidney disease and its progressionAntihypertensive agents for preventing diabetic kidney diseasePentoxifylline for diabetic kidney diseaseAntihypertensive agents for preventing the progression of diabetic kidney diseaseHeparin and related substances for preventing diabetic kidney diseaseSodium ferulate for preventing the progression of diabetic kidney diseaseVitamin B and/or its derivatives for diabetic kidney diseaseAntihypertensive agents for preventing the progression of diabetic kidney diseasePentoxifylline for diabetic kidney diseaseAngiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseAntihypertensive agents for preventing diabetic kidney diseaseCystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM studyEffects of diabetes and hypertension on macrophage infiltration and matrix expansion in the rat kidneyEarly detection of diabetic kidney disease: Present limitations and future perspectivesImmune Cells and Inflammation in Diabetic NephropathyMicroRNAs in Diabetic Kidney DiseaseDiabetes and end-stage renal disease; a review article on new conceptsEffective Delivery of Endogenous Antioxidants Ameliorates Diabetic NephropathyAblation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure.GPR119 agonists for the treatment of type 2 diabetesProtection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease.The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease.Prevalence and determinants of microalbuminuria among diabetic patients in the United Arab Emirates.Prevalence of asymptomatic bacteriuria in type 2 diabetic subjects with and without microalbuminuriaPrevalence of microalbuminuria and its risk factors in type 2 diabetic patientsRole of podocyte B7-1 in diabetic nephropathyPrevalence of microalbuminuria and risk factor analysis in type 2 diabetes patients in Albania: the need for accurate and early diagnosis of diabetic nephropathy.The effect of chromium picolinate supplementation on the pancreas and macroangiopathy in type II diabetes mellitus rats.Anemia is associated with the progression of white matter disease in older adults with high blood pressure: the cardiovascular health studyAcetyl-l-carnitine inhibits TNF-alpha-induced insulin resistance via AMPK pathway in rat skeletal muscle cells.Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes.Diabetic kidney disease: from epidemiology to clinical perspectives.Null association between ACE gene I/D polymorphism and diabetic nephropathy among multiethnic Malaysian subjects.Slowing the progression of renal disease in diabetic patients.Biochemistry and clinical role of human cystatin C.Insulin sensitivity is an important determinant of renal health in adolescents with type 2 diabetes.Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis.Potential methods to prevent interstitial fibrosis in renal disease.Reducing potentially avoidable complications in patients with chronic diseases: the Prometheus Payment approach
P2860
Q24186641-EFD4F744-70E2-4C8E-A862-F9D0899A3BCDQ24198925-64366426-5AE5-455B-A6D9-7678A24D2CD2Q24202090-DD136212-7411-43F3-8FA4-A875AA4A00B6Q24203643-F96B8832-C96C-4522-BAC2-BAB59432C022Q24234995-4F12BA90-EC26-4227-8554-10CCEFA99DE7Q24235372-7EA2679E-4E86-44AA-A57F-110B7DE0D51BQ24236054-E9643292-D06A-4ED7-BAF4-14BEB2A7D433Q24236375-1CCDFC10-8ECF-4A7A-89E4-5D24D54A164AQ24240735-EA22E71D-7514-44E6-BEAC-4D556C6BE55CQ24243734-D22F897C-1F03-42E4-AD1D-DD7660AB7310Q24244197-FC69BD99-F9AF-4819-8AE3-72213ACA3FABQ24245557-C375393A-577C-47C0-AD8F-C2D1046C6457Q24635177-2613F150-D73F-4A33-BBBB-2ABF8DA95569Q24810948-83354EB0-95E9-4671-A7DC-F254C15F6AD4Q26741494-7C85D5E8-B9C9-470A-A9DB-775D1A54C333Q26772998-4326AE4D-DF00-469B-A149-B49D9BBDD4AAQ27002171-1B6BD009-1AB6-4FF4-8CEC-33F9A087E407Q27023025-2A3793F7-5C7E-46DF-A299-989C7348D196Q27303768-336B882E-154A-40FA-BE34-84940772536AQ27347280-0790626A-434F-4088-8AD9-6529AE827DF6Q28259606-F2C196E8-A6DB-4BB2-99D4-19813E07BB34Q30249156-807ACE00-8F3B-4735-A6BD-10FCBB97C93DQ30340930-2909D4F9-5849-490A-B940-7738311DCE97Q33317048-B1AD81FB-765E-4AC8-86D7-3AFB8760C976Q33610748-034F7374-4661-4FAB-A016-E0B93E041F11Q33617447-2CFC407C-3040-44BF-9A1A-99504E3EB690Q33814864-429D1FB6-47E9-437B-AB06-6410E6214EAAQ33899286-B6BE5AB5-D4F9-4E85-94EF-81CADBAC8846Q33905136-AA3E7446-C1D5-47D3-A4C3-820E71A4221AQ33961569-ECC03DF7-4988-4DD8-9308-AB5249DE621FQ34015494-9A18E556-8DBF-424A-AEA2-05DCDB545019Q34075171-39A823AA-3EA2-4614-B12D-0A85D5E4ED77Q34161874-773784A4-36EE-47D7-8C8E-CEE73FCD0B61Q34204848-EC15AB7B-F31E-440B-BBD3-3C08D7D89270Q34219071-0743B908-9331-4950-A561-9D64C82EDDACQ34377103-05C80672-C68E-42E3-9A03-5DF8E903F077Q34392364-BFB5FF10-EF38-4EDC-BE40-A17F05E06E96Q34434218-14C7DF65-4B63-495F-94EC-222798817760Q34481843-9E2AD039-FF69-4D57-BA63-8E13045C6588Q34534589-A2EE594A-5C6E-4CAA-B209-AFDB79F9102E
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Nephropathy in patients with type 2 diabetes mellitus.
@ast
Nephropathy in patients with type 2 diabetes mellitus.
@en
type
label
Nephropathy in patients with type 2 diabetes mellitus.
@ast
Nephropathy in patients with type 2 diabetes mellitus.
@en
prefLabel
Nephropathy in patients with type 2 diabetes mellitus.
@ast
Nephropathy in patients with type 2 diabetes mellitus.
@en
P1476
Nephropathy in patients with type 2 diabetes mellitus.
@en
P304
P356
10.1056/NEJM199910073411506
P407
P577
1999-10-01T00:00:00Z